The complaint charged that J&J subsidiary Janssen Pharmaceuticals promoted Risperdal for unapproved uses, including dementia in elderly patients, schizophrenia and bi-polar disorder in children and adolescents, and depression to name a few. These uses were allegedly not approved by the Food and Drug Administration.
States receiving a portion of the settlement are Alabama, Arizona, Colorado, Connecticut, Delaware, District of Columbia, Florida, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Maine, Maryland, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Washington, Wisconsin and Wyoming.
More Articles on Pharmaceutical Companies and Fraud:
Johnson & Johnson Slapped With $1.1B Fine for Risperdal Marketing
Drugmakers Pay More Than $8B in Fraud Fines in Past Decade
Insurers Tailor Plans for Healthcare Executives Facing Misdemeanor Fraud Charges
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.